ClinicalTrials.gg
CompletedNCT01380600Updated Jul 8, 2026Results posted

Phase 1b Dose Escalation Study of Intravenous JX-594 in Metastatic, Refractory Colorectal Carcinoma

A Phase 1 interventional study of Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594) in Carcinoma, Colorectal, sponsored by Jennerex Biotherapeutics. Completed at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Jennerex Biotherapeutics · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 283 studies in Colorectal Neoplasms with a site in Korea, Republic of — 60 open to participants now, 95 under way, 13 of them phase 3. Colorectal Neoplasms · Korea, Republic of.

Enrollment
240th of 251
15 · median 150
Started
2010
with 11 others
Phase 1
53 of 283
14 open now
Registered
49th of 283
by date

Among the 283 studies in Colorectal Neoplasms with a site in Korea, Republic of, this one is the 240th largest by enrollment of the 251 interventional ones that give a count, is one of 12 that started in 2010, is one of 53 in phase 1, and was the 49th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

60 of the 283 studies in Colorectal Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Colorectal Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this pilot safety study is to evaluate the safety and tolerability of JX-594 (Pexa-Vec) administered intravenously every 2 weeks in colorectal carcinoma patients who are refractory to or intolerant of oxaliplatin, irinotecan, and Erbitux treatments.

Read the detailed description

This is a Phase Ib, open-label, dose-escalation study designed to evaluate the safety and tolerability of Pexa-Vec (JX-594), a vaccinia GM-CSF/thymidine kinase-deactivated virus, administered intravenously in patients with advanced/metastatic colorectal carcinoma (CRC) that is refractory to standard therapy. Vaccinia virus, from which Pexa-Vec is derived, shows a natural selectivity toward cancer relative to normal tissues after intravenous (IV) administration.

The study utilizes a sequential dose-escalating design to determine the maximum tolerated dose (MTD) and/or maximum feasible dose (MFD). Patients will receive 4 biweekly treatments of Pexa-Vec administered by IV infusion over 60 minutes on Days 1, 15, 29, and 43. Patients will be sequentially enrolled into one of three dose cohorts:

  • Cohort 1: 1 × 10\^6 pfu/kg
  • Cohort 2: 1 × 10\^7 pfu/kg
  • Cohort 3: 3 × 10\^7 pfu/kg Three patients will be treated at each dose level unless a dose-limiting toxicity (DLT) is observed, at which point the cohort may be expanded. All patients will receive hydration and will be observed in the clinic and/or hospital for a minimum of 24 hours after each infusion.

In addition to safety endpoints, secondary objectives include the evaluation of Pexa-Vec pharmacokinetics (PK), pharmacodynamics, immune response, and preliminary anti-tumoral activity. Tumor response assessments will be conducted using CT or MRI on Days 29 and 57 (±2 days) based on Response Evaluation Criteria in Solid Tumors (RECIST).

03

Conditions studied

  • Carcinoma, Colorectal

Keywords

  • Vaccinia
  • Vaccinia Virus
  • JX-594
  • Jennerex
  • Colorectal Carcinoma
  • Colorectal cancer
  • Colon Cancer
  • Rectal Cancer
  • Pexa-Vec
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -confirmed, advanced/ colorectal carcinoma
  • Failed both oxaliplatin and irinotecan based regimens for advanced/metastatic disease (if tumor advanced either immediately or within 3 months of the end of treatment)
  • Resistance to Erbitux: patients with Ras mutations, or for whom Erbitux has failed (if tumor advanced either immediately or within 3 months of the end of treatment, or there is no response to Erbitux therapy due to a lack of expression of EGFR (epidermal growth factor))
  • Performance Score (KPS) ≥ 70
  • Age ≥18 years
  • Laboratory Safety: WBC ≥ 3,500 cells/mm3 and ≤ 50,000 cells/mm3, ≥ 1,500 cells/mm3, ≥ 10 g/dL (transfusion allowed), count ≥ 100,000 plts/mm3,Total ≤ 1.5 X , ≤ 1.5, , ALT ≤ 2.5x ULN (in case of liver metastasis: AST,ALT ≤5.0 x ULN)
  • Serum chemistries within normal limits (WNL) or Grade 1 (excluding alkaline phosphatase) - If patients are diabetic, a fasting glucose must be done and patients must be > 160 mg/dL.
  • Patients who, if they are sexually active, are willing and able to refrain from sexual activity for 3 weeks following JX-594 administration. Patients who are willing and able to use a permitted for 3 months after the final administration of JX-594.

Exclusion criteria

Exclusion Criteria:

  • Significant immunodeficiency due to underlying illness (e.g. /AIDS) and/or medication (e.g. systemic )
  • Known myeloproliferative disorders requiring systemic therapy
  • History of exfoliative skin condition (e.g. eczema or ectopic dermatitis) requiring systemic therapy
  • History of acquiring opportunistic infections.
  • Tumor(s) invading a major vascular structure (e.g. carotid artery)
  • Tumor(s) in location that would potentially result in significant clinical adverse effects if post-treatment tumor swelling were to occur
  • Clinically uncontrolled and/or rapidly accumulating ascites, pericardial and/or pleural effusions
  • History of severe or unstable cardiac disease
  • Current, known CNS (history of completely resected or irradiated by WBRT or stereotactic radiosurgery allowed)
  • Administered anti-cancer therapy within 4 weeks prior to first treatment (6 weeks in case of mitomycin C or nitrosoureas)
  • Use of anti-viral, anti-, or anti-coagulation medication [Patients who discontinue such medications within 7 days prior to first treatment may be eligible for this study.] Low dose aspirin (approximately 81 mg) allowed.
  • Pulse oximetry O2 saturation \<90% Pulse oximetry O2 saturation \<90% at rest
  • Experienced a severe systemic reaction or side-effect as a result of a previous smallpox vaccination
  • Pregnant or nursing
  • Household contact exclusions:
  • Women who are pregnant or nursing an infant
  • Children \< 5 years old
  • People with skin disease (e.g. eczema, atopic dermatitis, and related diseases
  • hosts (severe deficiencies in cell-mediated immunity, including AIDS, organ transplant recipients, hematologic malignancies)
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Other
    single arm; Dose escalation

    Dose escalation 1e6 pfu/kg bw, 1e7 pfu/kg bw, 3e7 pfu/kg bw of Recombinant Vaccinia GM-CSF JX-594

    Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)

Interventions

  • DrugJX-594Studies of JX-594JX-594 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous Dose Range: 1x10\^6 pfu/kg, 1x10\^7 pfu/kg, 3x10\^7 pfu/kg Up to 4 intravenous infusions administered over 60 minutes every 2 weeks.

    Also known as: JX-594

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)

    A DLT is defined as any of the following treatment-related adverse events: Grade 4 toxicity, Grade 3 hematologic toxicity for \> 5 days, or Grade 3 non-hematologic toxicities persisting for \> 7 days except for flu-like symptoms that respond to standard therapies. The number of participants with DLTs was used to determine the Maximally-Tolerated Dose (MTD) and/or Maximum-Feasible Dose (MFD) of JX-594.

    Time frame: Up to Day 57 (assessed through 14 days following the 4th and final biweekly JX-594 infusion, an average of 8 weeks).

  2. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Adverse events were collected and assessed to evaluate safety and tolerability. A Treatment-Emergent Adverse Event (TEAE) is defined as an event with a start date on or after the date of the first dose of study treatment, or an event present at baseline that worsened in severity after the first dose.

    Time frame: Up to Day 71 (assessed through 28 days following the 4th and final biweekly JX-594 infusion, an average of 10 weeks).

Secondary outcomes

  1. Number of Participants in Each Best Overall Tumor Response Category Based on RECIST

    Anti-tumoral response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) on CT or MRI. Categories include: Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR) = \>=30% decrease in the sum of the longest diameters of target lesions; Progressive Disease (PD) = \>=20% increase in the sum of the longest diameters of target lesions or appearance of new lesions; Stable Disease (SD) = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

    Time frame: Up to Day 57 (Week 8)

  2. Overall Survival (OS)

    Overall survival (OS) was defined as the time from the first dose of Pexa-Vec until death from any cause. For patients not known to have died at the time of the analysis, OS was censored on the date they were last known to be alive.

    Time frame: From the first dose of Pexa-Vec until death from any cause, assessed up to 24 months

07

Results

Posted Jul 8, 2026

Participant flow

Patients with metastatic, refractory colorectal carcinoma who had failed both oxaliplatin- and irinotecan-based prior chemotherapy regimens were recruited at a single study site (Samsung Medical Center) in Seoul, Republic of Korea. The recruitment and study conduct took place between September 08, 2010, and October 18, 2012

Participant flow — Overall Study
MilestoneCohort 1: Pexa-Vec 1 × 10^6 Pfu/kgCohort 2: Pexa-Vec 1 × 10^7 Pfu/kgCohort 3: Pexa-Vec 3 × 10^7 Pfu/kg
Started339
Completed227
Not completed112

Outcome measures

PrimaryNumber of Participants Experiencing Dose-Limiting Toxicities (DLTs)

A DLT is defined as any of the following treatment-related adverse events: Grade 4 toxicity, Grade 3 hematologic toxicity for \> 5 days, or Grade 3 non-hematologic toxicities persisting for \> 7 days except for flu-like symptoms that respond to standard therapies. The number of participants with DLTs was used to determine the Maximally-Tolerated Dose (MTD) and/or Maximum-Feasible Dose (MFD) of JX-594.

Time frame:
Up to Day 57 (assessed through 14 days following the 4th and final biweekly JX-594 infusion, an average of 8 weeks).
Reported as:
Count of participants · Participants
Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
ParticipantsCohort 1: Pexa-Vec 1 × 10^6 Pfu/kgCohort 2: Pexa-Vec 1 × 10^7 Pfu/kgCohort 3: Pexa-Vec 3 × 10^7 Pfu/kg
Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)000
PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

Adverse events were collected and assessed to evaluate safety and tolerability. A Treatment-Emergent Adverse Event (TEAE) is defined as an event with a start date on or after the date of the first dose of study treatment, or an event present at baseline that worsened in severity after the first dose.

Time frame:
Up to Day 71 (assessed through 28 days following the 4th and final biweekly JX-594 infusion, an average of 10 weeks).
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsCohort 1: Pexa-Vec 1 × 10^6 Pfu/kgCohort 2: Pexa-Vec 1 × 10^7 Pfu/kgCohort 3: Pexa-Vec 3 × 10^7 Pfu/kg
Experienced TEAE339
Did NOT Experience TEAE000
SecondaryNumber of Participants in Each Best Overall Tumor Response Category Based on RECIST

Anti-tumoral response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) on CT or MRI. Categories include: Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR) = \>=30% decrease in the sum of the longest diameters of target lesions; Progressive Disease (PD) = \>=20% increase in the sum of the longest diameters of target lesions or appearance of new lesions; Stable Disease (SD) = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Time frame:
Up to Day 57 (Week 8)
Reported as:
Count of participants · Participants
Number of Participants in Each Best Overall Tumor Response Category Based on RECIST
ParticipantsCohort 1: Pexa-Vec 1 × 10^6 Pfu/kgCohort 2: Pexa-Vec 1 × 10^7 Pfu/kgCohort 3: Pexa-Vec 3 × 10^7 Pfu/kg
Complete Response000
Partial Response000
Stable Disease025
Progressive Disease202
No Post-Baseline Assessment112
SecondaryOverall Survival (OS)

Overall survival (OS) was defined as the time from the first dose of Pexa-Vec until death from any cause. For patients not known to have died at the time of the analysis, OS was censored on the date they were last known to be alive.

Time frame:
From the first dose of Pexa-Vec until death from any cause, assessed up to 24 months
Reported as:
Median · months
Overall Survival (OS)
monthsCohort 1: Pexa-Vec 1 × 10^6 Pfu/kgCohort 2: Pexa-Vec 1 × 10^7 Pfu/kgCohort 3: Pexa-Vec 3 × 10^7 Pfu/kg
Overall Survival (OS)10.4 (10.19 to 10.61)5.06 (NA to NA)10.22 (5.06 to 11.43)

Adverse events

Collected over Up to approximately 24 months (from the first dose until study completion). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Pexa-Vec 1 × 10^6 Pfu/kg2/3 (66.7%)0/3 (0%)3/3 (100%)
Cohort 2: Pexa-Vec 1 × 10^7 Pfu/kg1/3 (33.3%)0/3 (0%)3/3 (100%)
Cohort 3: Pexa-Vec 3 × 10^7 Pfu/kg5/9 (55.6%)2/9 (22.2%)9/9 (100%)
Most frequent serious events
Most frequent serious events
EventCohort 1: Pexa-Vec 1 × 10^6 Pfu/kgCohort 2: Pexa-Vec 1 × 10^7 Pfu/kgCohort 3: Pexa-Vec 3 × 10^7 Pfu/kg
Pneumonia necrotisingInfections and infestations0/30/31/9
Disease progressionGeneral disorders0/30/31/9
Most frequent other events
Showing 10 of 40
Most frequent other events
EventCohort 1: Pexa-Vec 1 × 10^6 Pfu/kgCohort 2: Pexa-Vec 1 × 10^7 Pfu/kgCohort 3: Pexa-Vec 3 × 10^7 Pfu/kg
PyrexiaGeneral disorders3/33/38/9
ChillsGeneral disorders1/33/39/9
NauseaGastrointestinal disorders3/32/34/9
HeadacheNervous system disorders2/33/34/9
Rash pustularInfections and infestations0/30/37/9
HypotensionVascular disorders1/31/34/9
FatigueGeneral disorders1/31/31/9
VomitingGastrointestinal disorders1/30/33/9
StomatitisGastrointestinal disorders0/31/32/9
DiarrhoeaGastrointestinal disorders1/31/31/9

Baseline characteristics

The baseline analysis population is based on the Intent-to-Treat (ITT) population, which includes all enrolled patients who received at least one treatment of Pexa-Vec

Age, Continuous
Age, Continuous(Years)Cohort 1: Pexa-Vec 1 × 10^6 Pfu/kgCohort 2: Pexa-Vec 1 × 10^7 Pfu/kgCohort 3: Pexa-Vec 3 × 10^7 Pfu/kgTotal
Mean46 ± 13.4556.3 ± 10.9756.7 ± 13.1554.5 ± 12.69
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Pexa-Vec 1 × 10^6 Pfu/kgCohort 2: Pexa-Vec 1 × 10^7 Pfu/kgCohort 3: Pexa-Vec 3 × 10^7 Pfu/kgTotal
Female2215
Male11810
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Pexa-Vec 1 × 10^6 Pfu/kgCohort 2: Pexa-Vec 1 × 10^7 Pfu/kgCohort 3: Pexa-Vec 3 × 10^7 Pfu/kgTotal
American Indian or Alaska Native0000
Asian33915
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Cohort 1: Pexa-Vec 1 × 10^6 Pfu/kgCohort 2: Pexa-Vec 1 × 10^7 Pfu/kgCohort 3: Pexa-Vec 3 × 10^7 Pfu/kgTotal
South Korea33915
American Joint Committee on Cancer (AJCC) Staging
American Joint Committee on Cancer (AJCC) Staging(Participants)Cohort 1: Pexa-Vec 1 × 10^6 Pfu/kgCohort 2: Pexa-Vec 1 × 10^7 Pfu/kgCohort 3: Pexa-Vec 3 × 10^7 Pfu/kgTotal
Stage IVA2002
Stage IVB13913
KRAS Mutational Status
KRAS Mutational Status(Participants)Cohort 1: Pexa-Vec 1 × 10^6 Pfu/kgCohort 2: Pexa-Vec 1 × 10^7 Pfu/kgCohort 3: Pexa-Vec 3 × 10^7 Pfu/kgTotal
Wild-type21811
Mutant1113
Not Assessed0101
Received Smallpox Vaccine
Received Smallpox Vaccine(Participants)Cohort 1: Pexa-Vec 1 × 10^6 Pfu/kgCohort 2: Pexa-Vec 1 × 10^7 Pfu/kgCohort 3: Pexa-Vec 3 × 10^7 Pfu/kgTotal
Yes2114
No0123
Unknown1168
08

Study locations

1 site
  • Samsung Medical Center
    Seoul, South Korea
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2026, 13 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2011
First posted
Jun 27, 2011
Start
Sep 8, 2010
Primary completionActual
Oct 18, 2012
CompletionActual
Oct 18, 2012
Results first posted
Jul 8, 2026
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01380600
Lead sponsor
Jennerex Biotherapeutics
Responsible party
Sponsor
First posted
Jun 27, 2011
Start date
Sep 8, 2010
Primary completion
Oct 18, 2012
Completion
Oct 18, 2012
Results posted
Jul 8, 2026
Last update
Jul 8, 2026

Study contacts

Young Suk Park, MD
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JX-594

Start the discussion